CN114931625A - 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 - Google Patents
尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 Download PDFInfo
- Publication number
- CN114931625A CN114931625A CN202210502257.1A CN202210502257A CN114931625A CN 114931625 A CN114931625 A CN 114931625A CN 202210502257 A CN202210502257 A CN 202210502257A CN 114931625 A CN114931625 A CN 114931625A
- Authority
- CN
- China
- Prior art keywords
- acid
- uridylic
- yeast peptide
- adenylic
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 60
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 title claims abstract description 58
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 title claims abstract description 58
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title claims abstract description 58
- 229950006790 adenosine phosphate Drugs 0.000 title claims abstract description 58
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 title claims abstract description 58
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 56
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 13
- 230000032683 aging Effects 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000002000 scavenging effect Effects 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 4
- 235000021436 nutraceutical agent Nutrition 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 5
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 5
- 235000013928 guanylic acid Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- -1 DPPH radicals Chemical class 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用,属于医药保健技术领域。所述组合物包括5’‑尿苷酸、5’‑腺苷酸和酵母肽,具有抗衰老的功能。本发明提供了包含5’‑尿苷酸、5’‑腺苷酸、酵母肽三种成分的组合物在抗衰老方面的应用,三种成分可以在肠道内彼此促进吸收,5’‑尿苷酸和5’‑腺苷酸与酵母肽在细胞和组织中可发挥协同作用,可高效清除DPPH和OH‑自由基,修复损伤细胞,提升抗氧化酶的活性,达到延缓衰老和抗衰老的目的。
Description
技术领域
本发明属于医药保健技术领域,具体涉及尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用。
背景技术
伴随着人口老龄化的加深,延缓衰老逐渐成为当前情势下迫切解决的之一。
延缓衰老在字面上可以理解为延缓机体的老化,包括细胞、组织,器官等的老化。可随着人们认知的发展,对于延缓衰老已经有了更加全面的认识,凡是有利于人体健康的,提高生活质量的,都可以认定为延缓衰老。延缓衰老的主要方式为非药物与药物两个方面,其中非药物的方法为坚持科学的生活规律,保持良好的生活习惯。而药物的方法分类就比较多,其中大多数是服用保健类药品或食品,其作用效果也是最显著的。
核苷酸是核糖核酸及脱氧核糖核酸的基本组成单位,是体内合成核酸的前身物。核苷酸随着核酸分布于生物体内各器官、组织、细胞的核及胞质中,并作为核酸的组成成分参与生物的遗传、发育、生长等基本生命活动。
发明内容
本发明的目的在于提供一种尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用。本发明经过长期研究,不同的核苷酸有不同的功能,搭配添加酵母肽后可以高效清除体内自由基,延缓细胞老化,恢复年轻态。本发明为核苷酸类营养品在提高人体健康水平、人们生活质量的应用方面提供了一种新思路。所得的成品具有延缓机体衰老、恢复年轻态等作用。
本发明为实现上述目的,通过以下技术方案实现:
一种尿苷酸、腺苷酸和酵母肽的组合物,所述组合物包括5’-尿苷酸、5’ -腺苷酸和酵母肽,具有抗衰老的功能。
进一步地,上述技术方案中,所述组合物包括如下重量配比的组分:5’- 尿苷酸14-63%、5’-腺苷酸9-50%、酵母肽1.5-77%。
进一步地,上述技术方案中,所述组合物包括如下重量配比的组分:5’- 尿苷酸40-60%、5’-腺苷酸25-50%、酵母肽10-30%。
进一步地,上述技术方案中,所述组合物包括如下重量配比的组分:5’- 尿苷酸41.5%、5’-腺苷酸41.5%、酵母肽17%;或者5’-尿苷酸52%、5’- 腺苷酸26%、酵母肽22%。
进一步地,上述技术方案中,所述组合物中5’-尿苷酸、5’-腺苷酸以5’ -单磷酸核苷酸或者钠盐形式存在,5’-腺苷酸与5’-尿苷酸的重量比为1:1-1:2。
进一步地,上述技术方案中,所述组合物的成品状态包括粉剂、颗粒剂、片剂、丸剂、口服液、胶囊。
本发明还提供了上述的尿苷酸、腺苷酸和酵母肽的组合物在制备抗衰老药品、保健品或营养食品中的应用。
进一步地,上述技术方案中,所述药品、保健品或营养食品具有清除体内自由基、抗氧化、对损伤细胞良好的保护和修复、延缓机体衰老、恢复年轻态的作用。
本发明相对于现有技术具有的有益效果如下:
本发明提供了包含5’-尿苷酸、5’-腺苷酸、酵母肽三种成分的组合物在抗衰老方面的应用。首先,本发明所使用的酵母肽是一种全营养酵母发酵产物,含500-2000Da以下短肽(5-20个氨基酸组成的肽)40%以上,还含有多糖、各种氨基酸和多种维生素矿物质以及膳食纤维补充衰老机体所缺各类营养成分。经过研究发现5’-尿苷酸、5’-腺苷酸可提升胃肠道益生菌存活率,改善肠道环境,促进大分子蛋白质分解,加速短肽的吸收与转运,与此同时短肽自身也可加速核苷酸、氨基酸、矿物质的吸收,并将其运输到人体组织所需处,二者互相促进。根据实验结果可以推测,核苷酸对酵母肽中氨基酸和多肽类物质抗氧化有调控作用,因此组合物加强了抗氧化作用并且减少氧化损伤引起的衰老。
附图说明
图1为本发明所述尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中谷胱甘肽过氧化物酶(GSH-PX)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P<0.05);*表示与空白组比较,差异有统计学意义(P<0.05)。
图2为本发明所述尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中超氧化物歧化酶(SOD)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P<0.05);*表示与空白组比较,差异有统计学意义(P<0.05)。
图3为本发明所述尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖小鼠血清中丙二醛(MDA)含量的影响。图中:#表示与模型组比较,差异有统计学意义(P <0.05)。
图4为本发明所述尿苷酸、腺苷酸和酵母肽的组合物对衰老小鼠寿命的影响。
具体实施方式
下面结合具体实施例对本发明的作进一步解释说明,这些实施例应被理解为仅是举例说明,而非以任何方式限制本发明的范围。下述实施例中,如无特殊说明,所使用的实验方法均为常规方法,所用材料、试剂等均可从生物或化学公司购买。
实施例1
按照重量配比为5’-尿苷酸14%、5’-腺苷酸14%、酵母肽72%在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例2
按照重量配比为5’-尿苷酸41.5%、5’-腺苷酸41.5%、酵母肽17%在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例3
按照重量配比为5’-尿苷酸49.25%、5’-腺苷酸49.25%、酵母肽1.5%在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例4
按照重量配比为5’-尿苷酸18%、5’-腺苷酸9%、酵母肽73%在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例5
按照重量配比为5’-尿苷酸52%、5’-腺苷酸26%、酵母肽22%在洁净区称取原料,用混合机混合均匀,得到粉剂。成品按质量标准的规定取样进行各项指标的检验,检验合格后保存备用。
实施例6尿苷酸、腺苷酸和酵母肽的组合物的抗氧化性能
将实施例1制备的粉剂,准备称重后溶解于去离子水和乙醇的混合溶液中 (体积比为1:1),制得浓度为1mg/mL的母液,进行DPPH自由基清除率的测定和OH-自由基清除率的测定。
1.DPPH自由基清除率的测定:
将母液分别稀释100,50,25,10,1倍制备成浓度为10μg/mL,20μg/mL, 40μg/mL,100μg/mL,500μg/mL的梯度稀释液。
分别取上述浓度150μL样品和150μL浓度为60mg/L的DPPH溶液(无水乙醇稀释)置于96孔板中,混合均匀,30℃避光保存,30min后使用酶标仪测量519nm 下吸光度值。DPPH自由基清除率公式如下:
式中,A空白为150μL去离子水乙醇溶液和150μL DPPH溶液的吸光度,A 样品为150μL样品和150μL DPPH溶液的吸光度;IC50为DPPH自由基清除率达到50%时样品的浓度。
2.OH-自由基清除率的测定:
(1)将母液分别稀释100,50,25,10,1倍制备成浓度为10μg/mL,20μg/mL, 40μg/mL,100μg/mL,500μg/mL的梯度稀释液。
(2)分别取上述浓度50μL样品和50μL浓度为6mmol/L的FeSO4溶液,加入50μL浓度为6mmol/L的乙醇-水杨酸溶液,置于96孔板中,混合均匀后,加入50μL浓度为6mmol/L的H2O2溶液,混合均匀。
(3)在37℃条件下反应30min后将96孔板放入酶标仪测量510nm下吸光度值(A样品)。OH-自由基清除率公式如下:
式中,A空白为用DMSO代替体系中的样品的吸光度,A样品为50μL样品的吸光度。IC50为OH-自由基清除率达到50%时样品的浓度。
实施例2-5制备的粉剂样品参照上述方法检测DPPH自由基清除率和OH-自由基清除率。对照组1:单组份5’-尿苷酸,对照组2:单组份5’-腺苷酸,对照组3:单组份酵母肽,对照组4:5’-尿苷酸和5’-腺苷酸按重量比1:1复配,对照组5:5’-鸟苷酸41.5%、5’-胞苷酸41.5%、酵母肽17%复配的组合物。实验数据以均值±标准偏差表示,实验结果如表1所示。
表1尿苷酸、腺苷酸和酵母肽的组合物的抗氧化性能
结果表明,与对照组1-5相比,实施例1-5的组合物均具有较高的抗氧化性能,表现出更强的清除DPPH自由基和OH-自由基的能力,尿苷酸、腺苷酸和酵母肽复配后抗氧化性能呈现显著增强的效果,实施例1-5的组合物能够更有效的清除机体的自由基,其中,以实施例2效果为最优。
本发明将尿苷酸、腺苷酸和酵母肽复配制备的组合物相较于单组份尿苷酸、单组份腺苷酸、单组份酵母肽、两种核苷酸复配(5’-尿苷酸和5’-腺苷酸按重量比1:1复配)或5’-鸟苷酸、5’-胞苷酸和酵母肽复配的混合物均具有显著的清除自由基的能力,清除DPPH自由基以及清除OH-自由基的能力得到成倍提升。同时可以增强生物体中抗氧化酶的活性,达到延缓衰老的目的。
实施例7尿苷酸、腺苷酸和酵母肽的组合物体外延缓衰老性能
以人脐静脉内皮细胞、PC-12细胞(大鼠肾上腺嗜铬细胞瘤细胞)为模型,采用H2O2造模,对实施例1-5的组合物进行细胞内ROS水平的评价。对照组1:单组份5’-尿苷酸,对照组2:单组份5’-腺苷酸,对照组3:单组份酵母肽,对照组4:5’-尿苷酸和5’-腺苷酸按重量比1:1复配,对照组5:5’-鸟苷酸41.5%、5’-胞苷酸41.5%、酵母肽17%复配的组合物。
H2O2作用细胞后产生大量ROS,攻击细胞膜、蛋白质及核酸,导致细胞损伤。将对数生长期的细胞消化成单细胞悬液,调节细胞浓度为105个/mL,接种于96 孔细胞培养板,每孔100μL,每组6个平行孔。接种24小时后,细胞贴壁生长,弃上清,加入终浓度200μmol/L的H2O2的培养基培养4h,然后替换为终浓度分别为50μg/mL的实施例1-5的组合物培养液继续培养24小时。实验同时设置不加H2O2的空白对照和只加H2O2的模型组,用活性氧检测试剂盒进行细胞内活性氧的状况评价:每孔加入10μmol/L的DCFH-DA母液(DMSO溶解),终浓度为1μmol/L。继续培养2小时后,弃去上清,每孔加PBS 100μL洗涤2次,离心后使用200μL的PBS重悬细胞,使用荧光酶标仪于激发波长485nm,发射波长为525nm条件下测定各孔荧光强度,计算细胞的活性氧含量。实验数据以均值±标准偏差表示,实验结果如表2所示。
表2人脐静脉内皮细胞和PC-12细胞内的活性氧含量
人脐静脉内皮细胞荧光强度 | PC-12细胞荧光强度 | |
模型组 | 20492±239 | 17783±148 |
实施例1 | 4672±151 | 4195±192 |
实施例2 | 3572±190 | 3551±170 |
实施例3 | 4408±171 | 4090±165 |
实施例4 | 4855±108 | 4363±149 |
实施例5 | 3861±137 | 3994±186 |
对照组1 | 14755±124 | 13498±174 |
对照组2 | 14872±168 | 13874±140 |
对照组3 | 16331±195 | 16004±108 |
对照组4 | 13072±164 | 12986±199 |
对照组5 | 13915±192 | 13080±167 |
上述结果表明,和模型组以及对照组1-5的组合物相比,实施例1-5的组合物能够显著降低模型细胞内的活性氧,实施例1-5的组合物对氧化损伤的细胞具有良好的保护和修复作用,其中,以实施例2效果为最优。
本发明将尿苷酸、腺苷酸和酵母肽复配制备的组合物相较于单组份尿苷酸、单组份腺苷酸、单组份酵母肽或两种核苷酸复配(5’-尿苷酸和5’-腺苷酸按重量比1:1复配)均具有显著的降低H2O2损伤的细胞内活性氧含量的能力,有助于使衰老氧化损伤的细胞得以修复,降低细胞内活性氧含量的能力得到成倍提升。
实施例8尿苷酸、腺苷酸和酵母肽的组合物对D-半乳糖诱导小鼠的作用
5周大的BALB/c小鼠,饲养一周后,其中20只用50mg/kg的D-半乳糖腹腔注射30天,30天后,以10只为一组。实验组:分别按照实施例1-5的组合物灌胃共28天,并同时腹腔注射D-半乳糖。对照组1:灌胃与组合物相同体积的5’-尿苷酸共28天,并同时腹腔注射D-半乳糖。对照组2:灌胃与组合物相同体积的5’-腺苷酸共28天,并同时腹腔注射D-半乳糖。对照组3:灌胃与组合物相同体积的酵母肽共28天,并同时腹腔注射D-半乳糖。对照组4:灌胃与组合物相同体积的5’-尿苷酸和5’-腺苷酸按重量比1:1复配的组合物共28天,并同时腹腔注射D-半乳糖。对照组5:灌胃与组合物相同体积的5’-鸟苷酸 41.5%、5’-胞苷酸41.5%、酵母肽17%复配的组合物共28天,并同时腹腔注射D-半乳糖。模型组:灌胃与组合物相同体积的PBS缓冲液。空白组:腹腔注射与D-半乳糖同等剂量的生理盐水,30天后灌胃与组合物相同体积的PBS缓冲液,同时持续腹腔注射,共28天。灌胃结束的第二天,眼眶采血后,用于后续实验。
实验结果如图1-图3所示,血清中氧化酶SOD和GSH-PX的含量均增加,丙二醛减少,说明本发明所述组合物能缓解D-半乳糖对小鼠的氧化损伤。与对照组1-4相比,实施例1-5所述的组合物均表现出更强的抗氧化损伤的能力,尿苷酸和腺苷酸与酵母肽协同作用,效果显著。
实施例9尿苷酸、腺苷酸和酵母肽的组合物对自然衰老小鼠衰老的延缓作用
8周大的BALB/c小鼠,随机分为两组,每组10只,实验组:分别按照实施例1-5的组合物灌胃至小鼠衰老自然死亡。空白组:灌胃同等提及的生理盐水至小鼠衰老自然死亡。对照组1:灌胃与组合物相同体积的5’-尿苷酸至小鼠衰老自然死亡。对照组2:灌胃与组合物相同体积的5’-腺苷酸至小鼠衰老自然死亡。对照组3:灌胃与组合物相同体积的酵母肽至小鼠衰老自然死亡。对照组4:灌胃与组合物相同体积的5’-尿苷酸和5’-腺苷酸按重量比1:1复配的组合物至小鼠衰老自然死亡。对照组5:灌胃与组合物相同体积的5’-鸟苷酸41.5%、5’- 胞苷酸41.5%、酵母肽17%复配的组合物至小鼠衰老自然死亡。
分别统计各组小鼠的生长寿命,结果如图4所示,本发明所述组合物可以有效延缓小鼠自然衰老。
对于任何熟悉本领域的技术人员而言,在不脱离本发明技术方案范围情况下,都可利用上述揭示的技术内容对本发明技术方案作出许多可能的变动和修饰,或修改为等同变化的等效实施例。因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均应仍属于本发明技术方案保护的范围内。
Claims (8)
1.一种尿苷酸、腺苷酸和酵母肽的组合物,其特征在于,所述组合物包括5’-尿苷酸、5’-腺苷酸和酵母肽,具有抗衰老的功能。
2.根据权利要求1所述的组合物,其特征在于,所述组合物包括如下重量配比的组分:5’-尿苷酸14-63%、5’-腺苷酸9-50%、酵母肽1.5-77%。
3.根据权利要求1所述的组合物,其特征在于,所述组合物包括如下重量配比的组分:5’-尿苷酸40-60%、5’-腺苷酸25-50%、酵母肽10-30%。
4.根据权利要求1所述的组合物,其特征在于,所述组合物包括如下重量配比的组分:5’-尿苷酸41.5%、5’-腺苷酸41.5%、酵母肽17%;或者5’-尿苷酸52%、5’-腺苷酸26%、酵母肽22%。
5.根据权利要求1-4中任一项所述的组合物,其特征在于,所述组合物中5’-尿苷酸、5’-腺苷酸以5’-单磷酸核苷酸或者钠盐形式存在,5’-腺苷酸与5’-尿苷酸的重量比为1:1-1:2。
6.根据权利要求1-5中任一项所述的组合物,其特征在于,所述组合物的成品状态包括粉剂、颗粒剂、片剂、丸剂、口服液、胶囊。
7.权利要求1-6中任一项所述的尿苷酸、腺苷酸和酵母肽的组合物在制备抗衰老药品、保健品或营养食品中的应用。
8.根据权利要求7所述的应用,其特征在于,所述药品、保健品或营养食品具有清除体内自由基、抗氧化、对损伤细胞良好的保护和修复、延缓机体衰老、恢复年轻态的作用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210502257.1A CN114931625A (zh) | 2022-05-09 | 2022-05-09 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
PCT/CN2023/091948 WO2023216952A1 (zh) | 2022-05-09 | 2023-05-04 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210502257.1A CN114931625A (zh) | 2022-05-09 | 2022-05-09 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114931625A true CN114931625A (zh) | 2022-08-23 |
Family
ID=82864843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210502257.1A Pending CN114931625A (zh) | 2022-05-09 | 2022-05-09 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114931625A (zh) |
WO (1) | WO2023216952A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023216952A1 (zh) * | 2022-05-09 | 2023-11-16 | 陈玉松 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
WO2023216951A1 (zh) * | 2022-05-09 | 2023-11-16 | 陈玉松 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646078A (zh) * | 2002-04-09 | 2005-07-27 | 大塚制药株式会社 | 细胞增殖用组合物 |
CN101147779A (zh) * | 2006-09-21 | 2008-03-26 | 珍奥集团股份有限公司 | 一种含有核苷酸的组合物、其制备方法及其用途 |
CN107557417A (zh) * | 2016-06-30 | 2018-01-09 | 安琪酵母股份有限公司 | 酵母多肽及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106135636B (zh) * | 2015-04-24 | 2020-01-03 | 安琪酵母股份有限公司 | 酵母来源的含尿苷酸的混合核苷酸及其制法和应用 |
US11833116B2 (en) * | 2020-08-25 | 2023-12-05 | Tci Co., Ltd. | Preparation method of yeast powder rich in nicotinamide mononucleotide, yeast powder, and methods for improving skin condition, hair health, antiinflammation, cardiovascular health, antioxidation, antiaging and/or relieving body fatigue |
CN113476470A (zh) * | 2021-07-30 | 2021-10-08 | 陈玉松 | 5’-核苷酸或其混合物在制备改善衰老细胞代谢的药物或功能食品中的应用 |
CN113577092B (zh) * | 2021-07-30 | 2022-07-01 | 陈玉松 | 一种延缓衰老的含核苷酸的组合物及其制备方法和应用 |
CN114931625A (zh) * | 2022-05-09 | 2022-08-23 | 大连双迪科技股份有限公司 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
-
2022
- 2022-05-09 CN CN202210502257.1A patent/CN114931625A/zh active Pending
-
2023
- 2023-05-04 WO PCT/CN2023/091948 patent/WO2023216952A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646078A (zh) * | 2002-04-09 | 2005-07-27 | 大塚制药株式会社 | 细胞增殖用组合物 |
CN101147779A (zh) * | 2006-09-21 | 2008-03-26 | 珍奥集团股份有限公司 | 一种含有核苷酸的组合物、其制备方法及其用途 |
CN107557417A (zh) * | 2016-06-30 | 2018-01-09 | 安琪酵母股份有限公司 | 酵母多肽及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
潘洪志: "核酸对大鼠体内抗氧化酶活力的影响", 《中国公共卫生》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023216952A1 (zh) * | 2022-05-09 | 2023-11-16 | 陈玉松 | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 |
WO2023216951A1 (zh) * | 2022-05-09 | 2023-11-16 | 陈玉松 | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023216952A1 (zh) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114931625A (zh) | 尿苷酸、腺苷酸和酵母肽组合物在抗衰老方面的应用 | |
CN103153320B (zh) | 用于抵抗衰老作用的口服制剂 | |
CN113577092B (zh) | 一种延缓衰老的含核苷酸的组合物及其制备方法和应用 | |
CN103333847A (zh) | 具有辅助降血脂功能的发酵乳杆菌grx08及其应用 | |
CN102908365A (zh) | 一种胚胎素的制备方法 | |
CN110218756A (zh) | 一种具有抗衰作用的富硒鲟鱼骨肽提取方法及产品 | |
WO2023216951A1 (zh) | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 | |
CN113876610B (zh) | 一种能够增强细胞能量并提高皮肤抵抗力的组合物及其制备方法与应用 | |
ES2526873T3 (es) | Procedimiento para la preparación de un producto natural fermentado | |
Mendes et al. | Agar content of estuarine seaweed Gracilaria using different cultivation methods | |
CN101356972B (zh) | 一种抗疲劳、耐缺氧的运动保健品 | |
CN117731693A (zh) | 基于掺杂的多酶活性纳米材料在治疗炎症性疾病中的应用 | |
CN101401649A (zh) | 可增强机体免疫力的组合物 | |
CN113170889A (zh) | 一种复方延缓衰老组合物、复方延缓衰老片及其制备方法和应用 | |
CN112245482B (zh) | 含有活性云母的组合物在制备提高细胞内超氧化物歧化酶活性的药物中的应用 | |
CN104026589A (zh) | 一种肽化酵素及其制备方法 | |
CN111789773A (zh) | 一种小分子水簇团组合物及其制备方法 | |
CN109602747B (zh) | 6-苄氨基嘌呤在制备预防和/或治疗急进高原导致的高原病的药物中的应用 | |
CN107519198A (zh) | 一种右旋糖酐铁注射液及其制备方法 | |
CN1190234C (zh) | 大规模工业化生产螺旋藻多营养素的生产工艺 | |
KR20210115240A (ko) | PDRN과 N-Acetylglucosamin을 유효성분으로 하는 미네랄의 흡수를 증가시키는 조성물의 제조 방법과 그 용도 | |
CN114656576B (zh) | 一种环磷酸腺苷-大枣酸性多糖复合物及制备方法与应用 | |
CN115192605B (zh) | 二巯基丁二酸修饰的四氧化三钴纳米颗粒的应用 | |
CN114044809B (zh) | 一种源于灵芝的抗氧化活性肽及其应用 | |
CN117338794A (zh) | 唾液酸在促进钙吸收中的应用及产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079445 Country of ref document: HK |